var data={"title":"Pentobarbital: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentobarbital: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6751?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pentobarbital-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pentobarbital: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pentobarbital-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pentobarbital: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208174\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nembutal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208175\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nembutal Sodium</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208200\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Barbiturate;</li>\n      <li>\n        Barbiturate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208178\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adjust dose based on patient's age, weight, and condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedative/hypnotic/preanesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 150 to 200 mg, as a single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 100 mg; if needed, may administer additional increments after at least 1 minute, up to a total dose of 200 to 500 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Seizures:</b> IV: <b>Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurocritical Care Society recommendations</i> (NCS [Brophy 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 5 to 15 mg/kg administered at a rate of &le;50 mg/minute, may give additional 5 to 10 mg/kg; follow with a continuous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: 0.5 to 5 mg/kg/hour. If the patient experiences breakthrough status epilepticus while on continuous infusion, administer an additional 5 mg/kg bolus and increase infusion rate by 0.5 to 1 mg/kg/hour every 12 hours. <b>Note:</b> A period of at least 24 to 48 hours of electrographic control is recommended prior to withdrawing the continuous infusion; withdraw gradually to prevent recurrent status epilepticus.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Barbiturate coma in severe brain injury patients/elevated intracranial pressure (off-label use):</b> IV: Loading dose: 10 mg/kg given over 30 minutes (or &le;25 mg/minute), followed by 5 mg/kg every hour for 3 doses; monitor blood pressure and respiratory rate. Maintenance infusion: Initial: 1 mg/kg/hour; may increase to 2 to 4 mg/kg/hour; maintain burst suppression on EEG (Censullo 2003; Eisenberg 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208190\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pentobarbital-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pentobarbital: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adjust dose based on patient's age, weight, and condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedative/hypnotic/preanesthesia:</b> <b>Infants, Children, and Adolescents:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 2 to 6 mg/kg as a single dose; maximum: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 1 to 6 mg/kg titrated in 1 to 2 mg/kg increments every 3 to 5 minutes to desired effect (Krauss 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Seizures:</b> Infants, Children, and Adolescents: IV: <b>Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurocritical Care Society recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 5 to 15 mg/kg administered slowly (eg, over 60 to 120 minutes [maximum rate: 50 mg/minute]), may give additional 5 to 10 mg/kg; follow with a continuous infusion (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: 0.5 to 5 mg/kg/hour. If the patient experiences breakthrough status epilepticus while on continuous infusion, administer an additional 5 mg/kg bolus and increase infusion rate by 0.5 to 1 mg/kg/hour every 12 hours. <b>Note:</b> A period of at least 24 to 48 hours of electrographic control is recommended prior to withdrawing the continuous infusion; withdraw gradually to prevent recurrent status epilepticus (NCS [Brophy 2012])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208179\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution, starting at low end of dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10583544\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, a reduced dosage is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> A risk of propylene glycol toxicity exists in patients receiving pentobarbital, especially in patients with renal impairment; monitor closely (eg, osmolal gap) if using for prolonged periods of time or at high doses (Miller 2008; Pillai 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208180\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. However, a reduced dosage is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208152\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nembutal: 50 mg/mL (20 mL, 50 mL) [latex free; contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (20 mL, 50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (20 mL, 50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208136\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208202\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208156\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer by deep IM or slow IV injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Inject into a large muscle. No more than 5 mL (250 mg) should be injected at any one site because of possible tissue irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Do not exceed 50 mg/minute; IV push doses may be given undiluted. Parenteral solutions are highly alkaline; avoid extravasation; avoid intra-arterial injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Seizures: Administer loading doses over 60 to 120 minutes (maximum rate: 50 mg/minute). Administer bolus doses over 10 to 30 minutes (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply warm compresses (Reynolds 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208155\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedative/hypnotic/preanesthesia</b>: Short-term (&lt;2 weeks) treatment of insomnia or as preanesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Seizures</b>: Emergency control of certain anticonvulsive episodes (eg, status epilepticus, cholera, eclampsia, meningitis, tetanus, toxic reactions to strychnine or local anesthetics).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: The American Academy of Sleep Medicine guidelines recommend against the use of barbiturates such as pentobarbital for the management of insomnia (AASM [Schutte-Rodin 2008]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744658\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Barbiturate coma in severe brain injury patients/elevated intracranial pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208210\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">PENTobarbital may be confused with PHENobarbital</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nembutal may be confused with Myambutol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Pentobarbital is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its high rate of physical dependence, tolerance to sleep benefits, and increased risk of overdose at low dosages (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Pentobarbital is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM)  performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208143\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, hypotension, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormality in thinking, agitation, anxiety, ataxia, central nervous system stimulation, confusion, depression, dizziness, drowsiness, hallucination, headache, insomnia, nervousness, nightmares, psychiatric disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Exfoliative dermatitis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Megaloblastic anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Hyperkinesia, laryngospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea (especially with rapid IV use), hypoventilation, respiratory depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208159\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to barbiturates or any component of the formulation; porphyria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208140\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: May cause respiratory depression particularly when administered intravenously; use with caution in patients with respiratory disease. Intubation is typically required prior to treatment for seizures or traumatic brain injury (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with depression or suicidal tendencies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reduce dose as appropriate. Do not use in patients showing premonitory signs of hepatic coma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; reduce dose as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Substance abuse: Use with caution in patients with a history of drug abuse; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in patients who are debilitated; marked excitement, depression, and confusion may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; marked excitement, depression, and confusion may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute or chronic pain: Use caution when administering to patients with acute or chronic pain; paradoxical excitement could be induced or important symptoms could be masked.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: IV administration: Solution for injection is highly alkaline and extravasation may cause local tissue damage. Too rapid IV administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208195\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Induces</b> CYP2A6 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208145\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9754&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers. <b> Exceptions: </b>Atenolol; Levobunolol; Metipranolol; Nadolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Chloramphenicol (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inducers): CYP2A6 Inducers (Strong) may increase the metabolism of CYP2A6 Substrates (High risk with Inducers).  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Barbiturates may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Felbamate. Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: Barbiturates may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Barbiturates may enhance the nephrotoxic effect of Methoxyflurane. Barbiturates may increase the metabolism of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Barbiturates may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: Barbiturates may increase the metabolism of Propacetamol. This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May increase the metabolism of Barbiturates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatostatin Acetate: May enhance the adverse/toxic effect of Barbiturates. Specifically, Somatostatin Acetate may enhance or prolong Barbiturate effects, including sedative effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Barbiturates may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.  Management: Monitor INR more closely. An anticoagulant dose increase may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208147\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10580824\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Barbiturates can be detected in the placenta, fetal liver and fetal brain. Fetal and maternal blood concentrations may be similar following parenteral administration. An increased incidence of fetal abnormalities may occur following maternal use. When used during the third trimester of pregnancy, withdrawal symptoms may occur in the neonate including seizures and hyperirritability; symptoms may be delayed up to 14 days. Use of hypnotic doses during labor does not impair uterine activity; however, use of full anesthetic doses decrease the force and frequency of uterine contractions. Respiratory depression may occur in the newborn when sedative-hypnotic barbiturates are administered to the mother during labor; resuscitation equipment should be available, especially for premature infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10580825\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Barbiturates are present in breast milk. The manufacturer recommends that caution be exercised when administering pentobarbital to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208149\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory status (for conscious sedation, includes pulse oximetry), cardiovascular status, CNS status; cardiac monitor and blood pressure monitor required; clinical signs of propylene glycol toxicity (for continuous high-dose and/or long duration IV use), including serum creatinine, BUN, serum lactate, and osmolal gap (Miller 2008; Pillai 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturate coma: Monitor oxygenation as well as arterial and central venous pressures to guide fluid and vasoactive therapy for maintenance of blood pressure; temperature</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elevated ICP: Monitor ICP, CPP, EEG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208153\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sedation: 1 to 5 mcg/mL (SI: 4 to 22 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coma or intracranial pressure therapy: Target: 30 to 40 mcg/mL (SI: 132 to 176 micromole/L) (Eisenberg 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potentially toxic: &gt;10 mcg/mL (SI: &gt;44 micromole/L); dependent on reason for use and patient condition</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208139\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Barbiturate with sedative, hypnotic, and anticonvulsant properties. Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit anticonvulsant activity; barbiturates produce dose-dependent respiratory depression; reduce brain metabolism and cerebral blood flow in order to decrease intracranial pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208158\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action (Krauss 2006): Children and Adults: Sedation: IM: 10 to 15 minutes; IV: Almost immediate, within 3 to 5 minutes; Oral, Rectal: 15 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (Krauss 2006): Children and Adults: Sedation: IM: 1 to 2 hours; IV: 15 to 45 minutes; Oral, Rectal: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Children: 0.8 L/kg (Schaible 1982); Adults: 1 L/kg (Ehrnebo 1974)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 45% to 70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via hydroxylation and glucuronidation (Wermeling 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: Children: 26 &plusmn; 16 hours (Schaible 1982); Adults: Healthy: 22 hours (average)  (Ehrnebo 1974); Range: 15 to 50 hours; dose dependent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;1%, as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570484\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nembutal Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (20 mL): $1,512.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (PENTobarbital Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (20 mL): $1,452.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038764\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dormital (UY);</li>\n      <li>Entobar (KR);</li>\n      <li>Medinox Mono (DE);</li>\n      <li>Nembutal (AT);</li>\n      <li>Pentone (AU);</li>\n      <li>Praecicalm (DE);</li>\n      <li>Prodormol (IL);</li>\n      <li>Sombutol (FI);</li>\n      <li>Sopental (ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27654000\"></a>Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. <i>Neurosurgery</i>. 2017;80(1):6-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/27654000/pubmed\" target=\"_blank\" id=\"27654000\">27654000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14593936\"></a>Censullo JL, Sebastian S. Pentobarbital sodium coma for refractory intracranial hypertension. <i>J Neurosci Nurs</i>. 2003;35(5):252-262.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/14593936/pubmed\" target=\"_blank\" id=\"14593936\">14593936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ehrnebo M, &ldquo;Pharmacokinetics and Distribution Properties Of Pentobarbital in Humans Following Oral and Intravenous Administration,&rdquo;<i>J Pharm Sci</i>, 1974, 63(7):1114-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/4853598/pubmed\" target=\"_blank\" id=\"4853598\">4853598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3288723\"></a>Eisenberg HM, Frankowski RF, Contant CF, Marshall LF, Walker MD. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. <i>J Neurosurg</i>. 1988;69(1):15-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/3288723/pubmed\" target=\"_blank\" id=\"3288723\">3288723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. <a href=\"https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm</a>. Published December 14, 2016. Accessed May 26, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta VD. Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes. <i>International Journal of Pharmaceutical Compounding.</i> 2001, 5(6): 482-484.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krauss B and Green SM, &ldquo;Procedural Sedation and Analgesia in Children,&rdquo; <i>Lancet</i>, 2006, 367(9512):766-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/16517277/pubmed\" target=\"_blank\" id=\"16517277\">16517277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller MA, Forni A, and Yogaratnam D, &ldquo;Propylene Glycol-Induced Lactic Acidosis in a Patient Receiving Continuous Infusion Pentobarbital,&rdquo; <i>Ann Pharmacother</i>, 2008, 42(10):1502-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/18698010/pubmed\" target=\"_blank\" id=\"18698010\">18698010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/25147175 /pubmed\" target=\"_blank\" id=\"25147175 \">25147175 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nembutol (pentobarbital) [prescribing information]. Lake Forest, IL: Akorn; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nembutal (pentobarbital sodium, solution) [prescribing information]. Lake Forest, IL: Akorn; April 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22926232\"></a>Pillai U, Hothi JC, Bhat ZY. Severe propylene glycol toxicity secondary to use of anti-epileptics. <i>Am J Ther</i>. 2014;21(4):e106-e109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/22926232/pubmed\" target=\"_blank\" id=\"22926232\">22926232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24420913\"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaible DH, Cupit GC, Swedlow DB, et al, &ldquo;High-Dose Pentobarbital Pharmacokinetics in Hypothermic Brain-Injured Children,&rdquo; <i>J Pediatr</i>, 1982, 100(4):655-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/7062221/pubmed\" target=\"_blank\" id=\"7062221\">7062221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18853708\"></a>Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. <i>J Clin Sleep Med</i>. 2008;4(5):487-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/18853708/pubmed\" target=\"_blank\" id=\"18853708\">18853708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sugai K, Sasaki M, Hanaoka S, et al. Practice of pentobarbital therapy in convulsive status epilepticus in children with epilepsy. Epilepsia. 1998; 19(S5):83. Available at http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1157.1998.tb01980.x/abstract</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7294399\"></a>Walker SE, Iazzetta J. Compatibility and stability of pentobarbital ininfusions. <i>Anesthesiology</i>. 1981;55(4):487-489.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/7294399/pubmed\" target=\"_blank\" id=\"7294399\">7294399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA. Pentobarbital pharmacokinetics in patients with severe head injury.<i> Drug Intell Clin Pharm</i>. 1987;21(5):459-463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/3582175/pubmed\" target=\"_blank\" id=\"3582175\">3582175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wermeling D, Record K, Bell R, et al, &ldquo;Hemodialysis Clearance of Pentobarbital During Continuous Infusion,&rdquo; <i>Ther Drug Monit</i>, 1985, 7(4):485-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/4082247/pubmed\" target=\"_blank\" id=\"4082247\">4082247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi: 10.1111/j.1525-139X.2007.00280.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9754 Version 195.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F208174\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F208175\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F208200\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F208178\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F208190\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F208179\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F10583544\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F208180\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F208152\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F208136\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F208202\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F208156\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F208155\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744658\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F208210\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F208143\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F208159\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F208140\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F208195\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F208145\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F208147\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10580824\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10580825\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F208149\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F208153\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F208139\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F208158\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570484\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038764\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9754|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pentobarbital-patient-drug-information\" class=\"drug drug_patient\">Pentobarbital: Patient drug information</a></li><li><a href=\"topic.htm?path=pentobarbital-pediatric-drug-information\" class=\"drug drug_pediatric\">Pentobarbital: Pediatric drug information</a></li></ul></div></div>","javascript":null}